IOVA Iovance Biotherapeutics, Inc. Stock Quote

IOVA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	0.10%	Shs Outstand	157.11M	Perf Week	9.20%
Market Cap	1.81B	Forward P/E	-	EPS next Y	-2.18	Insider Trans	-	Shs Float	144.23M	Perf Month	52.74%
Income	-358.40M	PEG	-	EPS next Q	-0.62	Inst Own	99.70%	Short Float	11.48%	Perf Quarter	-30.93%
Sales	-	P/S	-	EPS this Y	-18.90%	Inst Trans	1.75%	Short Ratio	3.31	Perf Half Y	-37.23%
Book/sh	3.51	P/B	3.42	EPS next Y	11.10%	ROA	-45.40%	Target Price	27.23	Perf Year	-53.24%
Cash/sh	3.19	P/C	3.76	EPS next 5Y	-	ROE	-54.80%	52W Range	6.18 - 27.96	Perf YTD	-37.19%
Dividend	-	P/FCF	-	EPS past 5Y	-3.80%	ROI	-	52W High	-57.10%	Beta	0.46
Dividend %	-	Quick Ratio	6.40	Sales past 5Y	-	Gross Margin	-	52W Low	94.09%	ATR	1.03
Employees	319	Current Ratio	6.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	60.50	Volatility	6.36% 9.43%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-13.90%	Profit Margin	-	Rel Volume	0.50	Prev Close	11.99
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 05 AMC	Payout	-	Avg Volume	5.00M	Price	11.99
Recom	1.90	SMA20	23.92%	SMA50	1.50%	SMA200	-30.22%	Volume	154,398	Change	0.04%

Jan-28-22

Upgrade

Stifel

Hold → Buy

$23 → $25

Dec-07-21

Resumed

Cowen

Outperform

Jun-10-21

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$32

May-20-21

Downgrade

Piper Sandler

Overweight → Neutral

$35 → $18

May-19-21

Downgrade

Stifel

Buy → Hold

May-19-21

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

May-03-21

Initiated

Truist

Buy

$50

Apr-16-21

Initiated

Goldman

Buy

$97

Mar-08-21

Upgrade

H.C. Wainwright

Neutral → Buy

$50

Dec-15-20

Downgrade

H.C. Wainwright

Buy → Neutral

Oct-06-20

Downgrade

Wells Fargo

Overweight → Equal Weight

Apr-22-20

Initiated

Mizuho

Buy

$61

Mar-04-20

Initiated

Barclays

Overweight

$45

Feb-26-20

Reiterated

Oppenheimer

Outperform

$32 → $35

Feb-26-20

Reiterated

H.C. Wainwright

Buy

$32 → $36

Dec-18-19

Initiated

JMP Securities

Mkt Outperform

$38

Oct-01-19

Initiated

Stifel

Buy

$27

Apr-29-19

Initiated

Piper Jaffray

Overweight

$20

Feb-28-19

Reiterated

Chardan Capital Markets

Buy

$30 → $20

Feb-07-19

Initiated

Robert W. Baird

Outperform

Jun-22-22 10:48AM	Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs Zacks +7.29%
Jun-17-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +7.75%
Jun-13-22 04:01PM	Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors GlobeNewswire -7.47%
Jun-12-22 09:00AM	Five Beaten-Up Biotech Stocks Saw Big Share Purchases Barrons.com
Jun-08-22 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire +9.86%
Jun-06-22 08:34PM	Down More Than 40%: Insiders Call a Bottom in These 2 Stocks TipRanks
Jun-05-22 09:06AM	Wayne Rothbaum Is The Independent Director of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) And They Just Picked Up 14% More Shares Simply Wall St.
Jun-03-22 06:52PM	Why Iovance Stock Leaped 17% Higher Today Motley Fool +18.94%
May-27-22 02:43PM	Iovance (IOVA) Down After Announcing Data From Melanoma Study Zacks -53.57%
01:08PM	Why Iovance Biotherapeutics Was Halved Today Motley Fool
09:57AM	Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting MarketWatch
May-26-22 04:29PM	Iovance's stock slides 40% after sharing data about its melanoma therapy MarketWatch
04:01PM	Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma GlobeNewswire
May-20-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-06-22 10:45AM	Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track Zacks
May-05-22 04:01PM	Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates GlobeNewswire -10.12%
Apr-27-22 04:01PM	Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting GlobeNewswire
Apr-26-22 07:30AM	Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022 GlobeNewswire -10.01%
Apr-25-22 04:01PM	Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit GlobeNewswire
Apr-22-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-12-22 04:01PM	CRISPR Therapeutics Proposes New Appointment to the Board of Directors GlobeNewswire
Apr-08-22 03:17PM	Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why Zacks
Apr-07-22 04:30PM	Here's The Bullish Sign From Iovance That Could Signal Its Turnaround Investor's Business Daily +7.62%
Apr-06-22 12:17PM	Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August Zacks
Apr-05-22 04:05PM	Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma GlobeNewswire
Mar-16-22 11:57AM	Iovance (IOVA) to Start Clinical Studies for TIL Therapy Zacks +7.03%
07:01AM	Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire
Mar-15-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
04:01PM	Iovance Biotherapeutics Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC) GlobeNewswire
Mar-08-22 04:31PM	Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting GlobeNewswire
Feb-25-22 09:59AM	Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss Zacks
Feb-24-22 04:01PM	Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates GlobeNewswire +5.24%
Feb-18-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-11-22 04:01PM	Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022 GlobeNewswire
Feb-07-22 12:01AM	Did The Smart Money Get Iovance Biotherapeutics, Inc. (IOVA) Right? Insider Monkey
Jan-21-22 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
09:38AM	Carnegie Capital Asset Management, LLC Buys Coinbase Global Inc, GXO Logistics Inc, Upstart ... GuruFocus.com
Jan-10-22 08:00AM	Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team GlobeNewswire -11.43%
Jan-07-22 04:01PM	Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® GlobeNewswire
Jan-06-22 05:38PM	Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022 GlobeNewswire
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... GuruFocus.com
Dec-17-21 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +9.44%
Dec-09-21 02:22PM	Hedge Funds Are Betting On Iovance Biotherapeutics, Inc. (IOVA) Insider Monkey
Dec-08-21 07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... GuruFocus.com
07:38PM	Tekla Healthcare Opportunities Fund Buys Moderna Inc, IDEXX Laboratories Inc, Sarepta ... GuruFocus.com
07:38PM	Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ... GuruFocus.com
Dec-07-21 08:40AM	Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire +10.93%
Nov-25-21 11:54AM	Cathie Wood Portfolio: 10 Biggest Losers Insider Monkey
Nov-19-21 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-15-21 10:12AM	Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers Benzinga -7.02%
Nov-13-21 04:30PM	Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-12-21 01:02PM	Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial Benzinga -10.34%
07:01AM	Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-10-21 09:05AM	Were These Hedge Funds Right About Dumping Iovance Biotherapeutics, Inc. (IOVA)? Insider Monkey -5.68%
Nov-09-21 08:54AM	Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-08-21 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire
Nov-05-21 07:02AM	Iovance (IOVA) Reports Wider-Than-Anticipated Loss in Q3 Zacks
12:32AM	Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript Motley Fool
Nov-04-21 04:01PM	Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates GlobeNewswire
Nov-03-21 07:04AM	Iovance Biotherapeutics (IOVA) Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-27-21 09:07AM	Wall Street Analysts Think Iovance Biotherapeutics (IOVA) Could Surge 52%: Read This Before Placing a Bet Zacks
Oct-25-21 04:01PM	Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021 GlobeNewswire
Oct-18-21 04:01PM	Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
09:26AM	Do Hedge Funds Love Iovance Biotherapeutics, Inc. (IOVA)? Insider Monkey
Oct-11-21 11:06AM	Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 49% as Wall Street Analysts Expect? Zacks
Oct-04-21 10:19PM	Iovance Biotherapeutics officially opens its $125M cell therapy center at the Philadelphia Navy Yard American City Business Journals
Oct-01-21 08:47AM	Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting GlobeNewswire +6.85%
Sep-28-21 05:00PM	Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC) in the Philadelphia Navy Yard GlobeNewswire
Sep-23-21 07:30AM	Iovance Biotherapeutics Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured at Iovance Cell Therapy Center (iCTC) GlobeNewswire
Sep-15-21 04:27PM	Why Iovance Is Up Nearly 11% Today Motley Fool +10.53%
Sep-06-21 01:11PM	Artisan Partners Remains Patient in Iovance Biotherapeutics (IOVA) Insider Monkey
Aug-16-21 08:36AM	Implied Volatility Surging for Iovance (IOVA) Stock Options Zacks
Aug-06-21 09:28AM	Iovance (IOVA) Q2 Earnings Miss Estimates, Pipeline in Focus Zacks
Aug-05-21 04:01PM	Iovance Biotherapeutics Reports Second Quarter and First Half 2021 Financial Results and Corporate Updates GlobeNewswire
Jul-19-21 04:30PM	Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021 GlobeNewswire
Jul-08-21 02:24AM	Why Iovance Biotherapeutics Soared 40% In June Motley Fool
Jun-30-21 10:07AM	Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy Zacks
Jun-29-21 03:38PM	Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET GlobeNewswire
09:12AM	Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients Benzinga
08:39AM	Iovance Drops After Update on Lung Cancer Treatment Study TheStreet.com
06:30AM	Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer GlobeNewswire
Jun-28-21 07:10PM	BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer GlobeNewswire
03:19PM	Is Iovance Biotherapeutics, Inc. (IOVA) A Good Stock To Buy? Insider Monkey
Jun-21-21 05:06AM	Inflation hasn't dented earnings forecasts Yahoo Finance
Jun-17-21 07:39AM	Should You Buy This Cathie Wood Biotech Stock? Motley Fool
Jun-07-21 08:26AM	Iovance's Lifileucel Shows Meaningful Increase in Response Time with Primary Anti-PD-1 Resistance in Melanoma Trial Benzinga +12.61%
Jun-06-21 09:24AM	Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting GlobeNewswire
Jun-04-21 09:08AM	Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting GlobeNewswire
Jun-01-21 07:30AM	Iovance Biotherapeutics to Present at Upcoming Conferences GlobeNewswire
May-25-21 04:47PM	10 Best Biotech Stocks to Buy According to Cathie Wood Insider Monkey
May-22-21 06:47AM	Here's Why Everyone's Talking About Iovance Biotherapeutics Motley Fool
May-20-21 04:03PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Iovance Biotherapeutics (IOVA) Investors With Losses and Persons Who May Assist Firm's Investigation Into Possible Securities Law Violations to Contact Its Attorneys Now PR Newswire +14.82%
12:20PM	Iovance Shares Jump After Lifileucel Achieves 86% Response Rate In Melanoma Trial Benzinga
10:40AM	Ademi LLP Investigates Claims of Securities Fraud against Iovance Biotherapeutics, Inc. PR Newswire
10:02AM	Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update Zacks
08:48AM	Is the Options Market Predicting a Spike in Iovance Biotherapeutics (IOVA) Stock? Zacks
May-19-21 10:52PM	The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors Business Wire -39.45%
08:50PM	2 Strong Buy Stocks Trading at Steep Discounts TipRanks
06:36PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Iovance Biotherapeutics (IOVA) Investors With Losses and Persons Who May Assist Firms Investigation Into Possible Securities Law Violations to Contact Its Attorneys Now GlobeNewswire
05:04PM	Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting GlobeNewswire

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Universite de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BILINSKY IGOR	Chief Operating Officer	Jun 14	Option Exercise	0.00	18,850	0	18,850	Jun 16 05:03 PM
Bellemin Jean-Marc	Chief Financial Officer	Jun 14	Option Exercise	0.00	18,850	0	18,850	Jun 16 05:03 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jun 14	Option Exercise	0.00	19,690	0	19,690	Jun 16 05:04 PM
Vogt Frederick G	Interim CEO & General Counsel	Jun 01	Buy	6.44	1,000	6,440	1,000	Jun 02 08:00 PM
Rothbaum Wayne P.	Director	Jun 01	Buy	6.43	500,000	3,215,500	8,067,333	Jun 02 07:59 PM
Rothbaum Wayne P.	Director	May 31	Buy	6.77	500,000	3,384,550	7,567,333	Jun 02 07:59 PM
Maynard Ryan D	Director	May 31	Buy	6.75	7,500	50,588	7,500	Jun 02 08:02 PM
MCPEAK MERRILL A	Director	May 31	Buy	6.80	10,000	68,000	218,633	Jun 02 08:03 PM
MCPEAK MERRILL A	Director	May 31	Buy	6.84	10,000	68,400	20,150	Jun 02 08:03 PM
WEISER MICHAEL	Director	May 31	Buy	6.80	10,000	67,978	112,632	Jun 02 08:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience